Jiangsu Egens Biotech Licenses Hepatitis C Diagnostic from Israel's BATM

Jiangsu Egens Biotechnology has in-licensed China rights to a hepatitis C diagnostic test from BATM, an Israeli networking technology company with a diagnostic subsidiary, Adaltis. In 2014, Egens and Adaltis set up a China JV to import diagnostic products. The CFDA approved Adaltis' hepatitis C diagnostic in 2015, and the JV has contracted with Sinopharm to distribute the device in China. Egens says it combines biological material development, diagnostic reagent manufacturing and trade. More details.... Stock Symbol: (LSE: BVC) Share this with colleagues: // //